Based on the encouraging results of above-mentioned studies, different clinical phase I and phase II trials are currently testing safety and efficiency of CD19 CAR T-cells in primary and secondary CNS lymphoma patients (Table 2). Here, CD19 is linked to primary central nervous system lymphoma.